CAP1-Derived Peptide Composition for Resistin–CAP1 Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Human resistin, a cytokine involved in inflammation and atherosclerosis, activates CAP1, leading to chronic inflammation and various diseases such as diabetes, atherosclerosis, and heart failure, for which effective therapeutic interventions are lacking.
Innovation Solution
A peptide comprising specific amino acid sequences, including SEQ ID NO: 1 (GPPPPPVSTS) with optional additions to the N- and C-terminus, inhibits the binding of CAP1 and resistin, thereby blocking the activation of NF-κB and AMPK pathways, reducing inflammation and metabolic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If human resistin activates CAP1, then inflammatory responses and disease progression occur, but no effective therapeutic intervention exists
Solution Approach 1:
The patent introduces a peptide molecule as an intermediary substance that binds to CAP1, preventing resistin from activating it. This peptide acts as a mediator that blocks the harmful resistin-CAP1 interaction without being the target itself, thereby providing therapeutic intervention against inflammation and disease progression
2Adaptability or versatility
If a peptide is designed to block CAP1-resistin binding, then inflammatory diseases can be treated, but the peptide structure must be precisely optimized
Solution Approach 1:
The patent systematically varies peptide sequence parameters (amino acid composition, length, and structure) to optimize binding inhibition capability. By changing these parameters and evaluating their effects on CAP1-resistin binding, the invention identifies optimal peptide sequences that effectively block the harmful interaction
Data Source
AI summary
The present invention relates to a polypeptide derived from CAP1 and a pharmaceutical composition comprising the same as an effective ingredient and, more particularly, to a peptide including the amino acid sequence of SEQ ID NO: 1, any 0 to 20 amino acid residues added to the N terminus thereof, and any 0 to 75 amino acid residues added to the C terminus thereof, and a pharmaceutical composition comprising the peptide as an effective ingredient for the prevention and alleviation of inflammatory diseases, the inhibition of cancer and cancer metastasis, the prevention and alleviation of diabetes, fatty hepatitis, arteriosclerosis, cardiovascular diseases, and heart failure. Exhibiting the effect of suppressing the binding of resistin to CAP1 and inhibiting NF-kB activity, the method of the present invention can be useful for treating inflammatory diseases, cancer, diabetes, fatty hepatitis, arteriosclerosis, cardiovascular diseases, and heart failure which are caused by the activation of resistin and NF-kB.